Skip to main content
Clinical Trials/NCT06516588
NCT06516588
Recruiting
Phase 2

Post-Stroke Cognitive Impairment: Neurovascular Mechanisms and Non-Invasive Brain Stimulation

University of Oklahoma1 site in 1 country80 target enrollmentSeptember 30, 2024

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Stroke
Sponsor
University of Oklahoma
Enrollment
80
Locations
1
Primary Endpoint
Montreal Cognitive Assessment (MoCA)
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

This study will evaluate the effects of a form of non-invasive brain stimulation on brain functioning and memory in participants with post-stroke cognitive impairment (PSCI).

Detailed Description

The goal of this study is to learn important information about the effects of electrical stimulation (Transcranial direct current stimulation (tDCS) on brain functioning in those with post-stroke cognitive impairment (PSCI). The findings will help determine how stimulation affects the brain's activity, cerebral blood flow, and circulating blood biomarkers of neuroinflammation after stroke. The study will use different forms of non-invasive brain imaging to see whether stimulation changes how the brain responds during a memory task. Functional near-infrared spectroscopy (fNIRS) and electroencephalograph (EEG) will be used, we will also collect blood samples for the biomarkers of inflammation. The study also uses cognitive tests and questionnaires.

Registry
clinicaltrials.gov
Start Date
September 30, 2024
End Date
June 30, 2027
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • ischemic stroke participants in sub-acute phase (at least 10 days after stroke event or discharge and under 5 months post-event) with cognitive dysfunction (MoCA \<26);

Exclusion Criteria

  • clinically significant or unstable medical or psychiatric condition;
  • diagnosis of severe depression;
  • history of relevant neurological diagnosis (e.g., epilepsy);
  • previous neurosurgical procedure with craniectomy;
  • contraindications to tDCS (implanted brain medical devices);
  • severe visual impairment, hearing impairment, aphasia, neglect or dementia.

Outcomes

Primary Outcomes

Montreal Cognitive Assessment (MoCA)

Time Frame: Changes from baseline after intervention week (two weeks), one and three months

It is a 30-point test about several cognitive domains (visuospatial/executive, naming, memory, attention, language, abstraction, delayed recall and orientation) and a screening tool used of MCI and dementia.

NIH Toolbox

Time Frame: Changes from baseline after one and three months

NIH Toolbox tests is a computarize test that acess fluid abilities (i.e., working memory, processing speed, episodic memory, and two aspects of executive functioning) and crystallized abilities (i.e., dependent upon past learning and experience), resulting in Standard Scores for these superordinate categories, as well as a total Composite score of all tests.These norms were previously reported to align with the age-corrected normative data for the traditional neuropsychological measures.

Secondary Outcomes

  • Neurovascular Coupling - Cerebral blood flow (fNIRS)(Changes on fNIRS signal from baseline after after intervention week (two weeks), one and three months)
  • Brain Function (EEG)(Changes on EEG signal from baseline after after intervention week (two weeks), one and three months)
  • Neurovascular Coupling - (DVA)(Changes on maximal arteriolar dilation and mean maximal venular dilation from baseline after intervention week (two weeks), one and three months)
  • Blood markers(Changes on blood marker levels from baseline after intervention week (two weeks), one and three months)

Study Sites (1)

Loading locations...

Similar Trials